Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients with Long COVID

NCT ID: NCT06822179

Last Updated: 2025-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-31

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme with monitoring via a mobile app produces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID.

The main questions it aims to answer are:

* Will a multimodal program (exercise with education) improve the self-management ability of patients with post-exertional malaise?
* Does fatigue and quality of life will be improved in these patients?

Researchers will compare an experimental breath program to a control standard care group to see if multimodal program works to treat post-exertion malaise.

Participants will:

* Follow-up 12 weeks online sessions:

1 weekly synchronous online session + 1 scheduled asynchronous session + educational resources
* Daily use of the app: daily log, education and questions

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long COVID Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-blind, randomized controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telerehabilitation program

The interventions include:

* Education for self-management
* Personalised exercise program

Group Type EXPERIMENTAL

Education for self-management

Intervention Type OTHER

Education program performed online including information, recommendations and guidance for promoting self-management

Personalised exercise program

Intervention Type OTHER

Individualized exercise that includes progressive load adapted to each patient. It includes making flexible adjustments to their exercise (up or down as needed) to help them gradually improve their physical abilities while staying within their energy limits

Control

Usual care

Group Type ACTIVE_COMPARATOR

Usual Care

Intervention Type OTHER

Usual care these patients may receive out from the clinical trial.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Education for self-management

Education program performed online including information, recommendations and guidance for promoting self-management

Intervention Type OTHER

Personalised exercise program

Individualized exercise that includes progressive load adapted to each patient. It includes making flexible adjustments to their exercise (up or down as needed) to help them gradually improve their physical abilities while staying within their energy limits

Intervention Type OTHER

Usual Care

Usual care these patients may receive out from the clinical trial.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post COVID-19 condition: individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction
* Between 18 and 75 years of age
* Possibility of access and use of smartphone.
* Ability to attend the clinic in person for an initial session.

Exclusion Criteria

* Patients with a history of respiratory or cardiovascular diseases prior to COVID-19, other acute or chronic diseases that may interfere with the study
* Pregnancy/breastfeeding
* Those with contraindications to respiratory muscle training.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CEU San Pablo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CEU San Pablo University

Madrid, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aitor Martin Pintado Zugasti

Role: CONTACT

+34 913724700

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aitor Martin-Pintado Zugasti, Phd

Role: primary

+34913724700

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEU-028

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.